Breast cancer up to 5 times more likely to metastasize even 10 years after childbirth

University of Colorado Cancer Center study shows that doctors may be underestimating the risk of and thus under-treating stage I and II breast cancers diagnosed within 10 years of childbirth.
16-Jan-2019 1:05 PM EST Add to Favorites

Cancer stem cells get energy from protein, and it’s proving to be their Achilles’ heel

CU Cancer Center study shows that cancer stem cells switch from metabolizing sugar to metabolizing protein. Turning off protein metabolism kills these cells.
12-Nov-2018 11:05 AM EST Add to Favorites

New combination treatment flips the switch on melanoma cells

Navitoclax plus A-1210477 not only killed melanoma cells, but also killed the melanoma initiating cells (aka cancer stem cells) that often resist therapy.
23-Oct-2018 12:05 PM EDT Add to Favorites

Cancer Stem Cells Use “Normal” Genes in Abnormal Ways

University of Colorado Cancer Center study shows that "normal" gene CDK1 interacts with "abnormal" gene Sox2 to keep cancer stem cells "stemmy."
12-Oct-2018 8:05 AM EDT Add to Favorites

Cancer Hijacks the Microbiome to Glut Itself on Glucose

A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.
28-Sep-2018 11:05 AM EDT Add to Favorites

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

Results of ALTA-1 trial: Patients given brigatinib saw a statistically significant 51 percent reduction in the risk of progression or death compared with those given crizotinib.
25-Sep-2018 8:05 AM EDT Add to Favorites

Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on...
24-Sep-2018 8:45 AM EDT Add to Favorites

New Combination Treatment Targets Pre-Leukemia Stem Cells

Omacetaxine (to block protein synthesis) with venetoclax (to block oxidative phosphorylation), was highly effective against CD123+ leukemia stem cells.
12-Sep-2018 1:05 PM EDT Add to Favorites

see all news